Enhancement of radioimmunotherapy by drugs modifying tumour blood flow in a colonic xenograft model

International Journal of Cancer

Volumn 57, Issue 6, 1994, Pages 830-835

  Pedley, R Barbara ^a   Begent, Richard H J ^a   Boden, Joan A ^a   Boxer, Geoffrey M ^a   Boden, Robert ^a   Keep, Patricia A ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IODINE 131; MITOFLAXONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; COLON ADENOCARCINOMA; CONTROLLED STUDY; DRUG DISTRIBUTION; FEMALE; IMMUNOMODULATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; TUMOR BLOOD FLOW; TUMOR NECROSIS; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; COLONIC NEOPLASMS; FEMALE; FLAVONOIDS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; REGIONAL BLOOD FLOW; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0028263706     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.2910570611     Document Type: Article

References (31)

1. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer
2. Flavone acetic acid—an interesting novel therapeutic agent orjust another disappointment?
3. Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347‐512)
4. Antitumour activity of flavone acetic acid (NSC 347512) in mice—influence of immune status
5. Radioimunotherapy of human colon carcinoma by 1311 labeled monoclonal anti‐CEA antibodies in the nude mouse model
6. Antitumour responses to flavone‐8‐acetic and 5.6‐dimethlxanthenone‐4‐acetic acid in immune deficient mice
7. Angiogenic attack as a therapeutic strategy for cancer
8. Comparison of distribution of intact and F(ab')2A5B7 antibodies in radioimmunotherapy
9. Natural killer (NK) and lymphokine activated killer (LAK) cell activity in patients (PTS) treated with flavone acetic acid (FAA)
10. Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts
11. Monoclonal antibody‐based therapies of leukemia and lymphoma
12. Vascular collapse after flavone acetic acid: a possible mechanism of its anti‐tumour action. Europ
13. Immunomodulation of natural killer cell activity by flavone acetic acid: occurrence via induction of interferon β
14. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma
15. A computer program for comparing K samples with right‐censored data
16. A mathematical evaluation of tumour growth curves in rapid. intermediate and slow growing rat hepatoma
17. Role of tumour necrosis factor in flavone acetic acid‐induced tumour vascular shutdown
18. Vascular damage and tumour response
19. Flavone acetic acid induces a coagulopathy in mice
20. Flavone acetic acid: is tumour endothelium a primary target?
21. 131I‐labelled anti‐CEA antibodies in a human colonic xenograft model
22. Relationship between tumour size and uptake of radiolabelled anti‐CEA in a colon tumour xenograft
23. Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry
24. Early spatial and temporal changes in tumour perfusion after administration of flavone acetic acid
25. Differential efficacy of flavone acetic acid against liver versus lung metastases in a human tumour xenograft
26. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid
27. Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin 2
28. Phase II trial with flavone acetic acid (NSC.347512, LM975) in patients with non‐small cell lung cancer
29. Potentiation of the anti‐tumour effect of melphalan by the vasoactive agent hydralizine
30. Human colonic adenocarcinoma cells. I. Establishment and description of a new cell line
31. Blood flow failure as a major determinant in the antitumour action of flavone acetic acid